POOLED SAFETY ANALYSIS OF BARICITINIB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM THREE RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CLINICAL TRIALS

被引：1
|
作者：
Dorner, T. [1 ]
Tanaka, Y. [2 ]
Mosca, M. [3 ]
Bruce, I. N. [4 ]
Cardiel, M. [5 ]
Morand, E. F. [6 ]
Petri, M. A. [7 ]
Silk, M. [8 ]
Dickson, C. [8 ]
Meszaros, G. [8 ]
Issa, M. [8 ]
Zhang, L. [8 ]
Wallace, D. J. [9 ]
机构：
[1] Charite, Med Rheumatol & Clin Immunol, Berlin, Germany
[2] Univ Occupat & Environm Hlth, First Dept Internal Med, Kitakyushu, Fukuoka, Japan
[3] Univ Pisa, Dept Clin & Expt Med, Pisa, Italy
[4] Univ Manchester, Div Musculoskeletal & Dermatol Sci, Manchester, Lancs, England
[5] Centro Investigac Clin Morelia, Clinical Res, Morelia, Michoacan, Mexico
[6] Monash Univ, Ctr Inflammatory Dis, Melbourne, Vic, Australia
[7] Johns Hopkins Univ, Div Rheumatol, Baltimore, MD USA
[8] Eli Lilly & Co, Indianapolis, IN USA
[9] Univ Calif Los Angeles, Cedars Sinai Med Ctr, Div Rheumatol Allergy & Immunol, Los Angeles, CA USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2022年 / 81卷
关键词：
D O I：
10.1136/annrheumdis-2022-eular.2375
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
POS0714
引用
收藏
页码：639 / 639
页数：1
相关论文
共 50 条
  • [41] HEPATIC SAFETY OF KARXT (XANOMELINE AND TROSPIUM CHLORIDE): POOLED RESULTS FROM THE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED EMERGENT TRIALS
    Claxton, Amy
    Marcus, Ronald
    Ruan, Shiling
    Kaul, Inder
    Sauder, Colin
    NEUROPSYCHOPHARMACOLOGY, 2024, 49 : 533 - 534
  • [42] Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies
    Nitti, V. W.
    Khullar, V.
    van Kerrebroeck, P.
    Herschorn, S.
    Cambronero, J.
    Angulo, J. C.
    Blauwet, M. B.
    Dorrepaal, C.
    Siddiqui, E.
    Martin, N. E.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2013, 67 (07) : 619 - 632
  • [43] Pooled Analysis of Cardiovascular Safety of Fremanezumab in Patients ≥60 Years of Age With Migraine: Pooled Results of 3 Randomised, Double-blind, Placebo-controlled Phase 3 Studies
    Naegel, S.
    Cohen, J. M.
    Kessler, Y.
    Ning, X.
    Yang, R.
    Kudrow, D.
    EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 1079 - 1080
  • [44] Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial
    Brunner, Hermine, I
    Abud-Mendoza, Carlos
    Viola, Diego O.
    Calvo Penades, Inmaculada
    Levy, Deborah
    Anton, Jordi
    Calderon, Julia E.
    Chasnyk, Vyacheslav G.
    Ferrandiz, Manuel A.
    Keltsev, Vladimir
    Paz Gastanaga, Maria E.
    Shishov, Michael
    Boteanu, Alina Lucica
    Henrickson, Michael
    Bass, Damon
    Clark, Kenneth
    Hammer, Anne
    Ji, Beulah N.
    Nino, Antonio
    Roth, David A.
    Struemper, Herbert
    Wang, Mei-Lun
    Martini, Alberto
    Lovell, Daniel
    Ruperto, Nicolino
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 (10) : 1340 - 1348
  • [45] Low-dose belimumab for patients with systemic lupus erythematosus at low disease activity: protocol for a multicentre, randomised, double-blind, placebo-controlled clinical trial
    Sun, Fangfang
    Huang, Wenyan
    Chen, Jie
    Zhao, Liling
    Zhang, Danting
    Wang, Xiaodong
    Wan, Weiguo
    Dai, Sheng-Ming
    Chen, Sheng
    Li, Ting
    Ye, Shuang
    LUPUS SCIENCE & MEDICINE, 2022, 9 (01):
  • [46] Safety and Tolerability Profile of Rifaximin for Treatment of IBS Without Constipation: Results of a Pooled Analysis of Double-Blind, Placebo-Controlled Randomized Controlled Trials
    Chang, Lin
    Chey, William D.
    Drossman, Douglas A.
    Lembo, Anthony
    Pimentel, Mark
    Schoenfeld, Philip S.
    Yu, Jing
    Merchant, Kunal
    Paterson, Craig
    Bortey, Enoch
    Forbes, William P.
    GASTROENTEROLOGY, 2012, 142 (05) : S823 - S823
  • [47] Cardiovascular safety of eptinezumab: A pooled analysis of double-blind, randomized, placebo-controlled studies
    Smith, T. R.
    Spierings, E. L. H.
    Cady, R.
    Hirman, J.
    Ettrup, A.
    Shen, V
    HEADACHE, 2021, 61 : 112 - 112
  • [48] Safety and tolerability of linagliptin in Asians with type 2 diabetes: a pooled analysis of 4457 patients from 21 randomized, double-blind, placebo-controlled clinical trials
    Kanasaki, Keizo
    Qu, Shen
    Yamamoto, Fumiko
    Schepers, Cornelia
    Simoes, Rafael Sani
    Yabe, Daisuke
    Ji, Linong
    EXPERT OPINION ON DRUG SAFETY, 2022, 21 (03) : 425 - 434
  • [49] Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study
    Isenberg, D. A.
    Petri, M.
    Kalunian, K.
    Tanaka, Y.
    Urowitz, M. B.
    Hoffman, R. W.
    Morgan-Cox, M.
    Iikuni, N.
    Silk, M.
    Wallace, D. J.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 (02) : 323 - 331
  • [50] Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials
    Mignot, Emmanuel
    Mayleben, David
    Fietze, Ingo
    Leger, Damien
    Zammit, Gary
    Bassetti, Claudio L. A.
    Pain, Scott
    Kinter, Dalma Seboek
    Roth, Thomas
    LANCET NEUROLOGY, 2022, 21 (02): : 125 - 139
12345